Latest Earnings Results: Q2 '26
Estimated EPS
-$0.24
Reported EPS
-$0.14
Surprise
+42.41%
Estimated Rev
$146.67M
Reported Rev
$151.04M
Surprise
+2.97%
• Reported GAAP EPS of -$0.14 down -150.00% YoY • Reported revenue of $151.04M down -12.65% YoY • 10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $610 million to $630 million, representing 2% to 5% growth over 2025.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.27 | -- | -- | N/A |
Q2 '26 | -$0.24 | -$0.14 | 42.41% | BEAT |
Q1 '26 | -$0.28 | -$0.10 | 63.65% | BEAT |
Q4 '25 | -$0.20 | -$0.13 | 35.89% | BEAT |
Q3 '25 | -$0.29 | -$0.22 | 23.71% | BEAT |